ANAPTYSBIO, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ANAPTYSBIO, INC. (ANAB) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$44.85 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-09-21
- ANAPTYSBIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$27.03M.
- ANAPTYSBIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$17.82M.
- ANAPTYSBIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$22.42M.
- ANAPTYSBIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$18.55M, a 651.55% decline year-over-year.
- ANAPTYSBIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$87.33M.
- ANAPTYSBIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$33.84M, a 409.36% decline from fiscal 2023.
- ANAPTYSBIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $10.94M, a 12.76% increase from fiscal 2022.
- ANAPTYSBIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $9.70M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$27.03M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$44.85M 10-KT · filed 2026-09-21 | -$67.27M derived: sum of 3 quarters · filed 2026-09-21 | -$85.83M derived: sum of 4 quarters · filed 2026-09-21 | ||||
| 2026-03-31 | -$17.82M 10-Q · filed 2026-05-12 | -$40.24M derived: sum of 2 quarters · filed 2026-09-21 | -$58.79M derived: sum of 3 quarters · filed 2026-09-21 | -$81.12M derived: sum of 4 quarters · filed 2026-09-21 | ||||
| 2025-12-31 | -$22.42M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$40.97M derived: sum of 2 quarters · filed 2026-09-21 | -$63.30M derived: sum of 3 quarters · filed 2026-09-21 | -$87.33M 10-KT · filed 2026-09-21 | -$87.33M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | -$18.55M derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | -$40.88M derived: sum of 2 quarters · filed 2026-09-21 | -$64.92M 10-Q · filed 2025-11-04 | -$104.96M derived: sum of 4 quarters · filed 2026-09-21 | ||||
| 2025-06-30 | -$22.33M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$46.36M 10-KT · filed 2026-09-21 | -$46.35M 10-Q · filed 2025-08-06 | -$86.41M derived: sum of 3 quarters · filed 2026-09-21 | -$83.05M derived: sum of 4 quarters · filed 2026-09-21 | |||
| 2025-03-31 | -$24.03M 10-Q · filed 2026-05-12 | -$64.08M derived: sum of 2 quarters · filed 2026-09-21 | -$60.72M derived: sum of 3 quarters · filed 2026-09-21 | -$52.70M derived: sum of 4 quarters · filed 2026-09-21 | ||||
| 2024-12-31 | -$40.05M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$36.68M derived: sum of 2 quarters · filed 2026-09-21 | -$28.67M derived: sum of 3 quarters · filed 2026-09-21 | -$33.84M 10-KT · filed 2026-09-21 | -$33.84M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $3.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $11.38M derived: sum of 2 quarters · filed 2025-11-04 | $6.21M 10-Q · filed 2025-11-04 | $4.71M derived: sum of 4 quarters · filed 2026-03-03 | ||||
| 2024-06-30 | $8.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.85M 10-Q · filed 2025-08-06 | $1.35M derived: sum of 3 quarters · filed 2026-03-03 | -$1.35M derived: sum of 4 quarters · filed 2026-03-03 | ||||
| 2024-03-31 | -$5.17M 10-Q · filed 2025-05-05 | -$6.67M derived: sum of 2 quarters · filed 2026-03-03 | -$9.37M derived: sum of 3 quarters · filed 2026-03-03 | -$2.77M derived: sum of 4 quarters · filed 2026-03-03 | ||||
| 2023-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$4.20M derived: sum of 2 quarters · filed 2026-03-03 | $2.40M derived: sum of 3 quarters · filed 2026-03-03 | $10.94M 10-K · filed 2026-03-03 | ||||
| 2023-09-30 | -$2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $3.90M derived: sum of 2 quarters · filed 2024-11-05 | $12.44M 10-Q · filed 2024-11-05 | $17.27M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $6.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $15.14M 10-Q · filed 2024-08-05 | $19.97M derived: sum of 3 quarters · filed 2025-02-27 | $21.23M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $8.53M 10-Q · filed 2024-05-09 | $13.37M derived: sum of 2 quarters · filed 2025-02-27 | $14.62M derived: sum of 3 quarters · filed 2025-02-27 | $14.70M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $4.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.09M derived: sum of 2 quarters · filed 2025-02-27 | $6.16M derived: sum of 3 quarters · filed 2025-02-27 | $9.70M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.33M derived: sum of 2 quarters · filed 2023-11-02 | $4.87M 10-Q · filed 2023-11-02 | -$453.00K derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2022-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $3.61M 10-Q · filed 2023-08-07 | -$1.71M derived: sum of 3 quarters · filed 2024-03-11 | -$1.90M derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2022-03-31 | $3.54M 10-Q · filed 2023-05-11 | -$1.78M derived: sum of 2 quarters · filed 2024-03-11 | -$1.98M derived: sum of 3 quarters · filed 2024-03-11 | $3.78M derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2021-12-31 | -$5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$5.51M derived: sum of 2 quarters · filed 2024-03-11 | $240.00K derived: sum of 3 quarters · filed 2024-03-11 | -$4.74M 10-K · filed 2024-03-11 | ||||
| 2021-09-30 | -$191.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $5.56M derived: sum of 2 quarters · filed 2022-11-08 | $581.00K 10-Q · filed 2022-11-08 | -$3.32M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $772.00K 10-Q · filed 2022-08-08 | -$3.13M derived: sum of 3 quarters · filed 2023-03-01 | $1.15M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | -$4.98M 10-Q · filed 2022-05-04 | -$5.13M 10-Q · filed 2021-05-04 | -$8.88M derived: sum of 2 quarters · filed 2023-03-01 | -$4.61M derived: sum of 3 quarters · filed 2023-03-01 | -$7.48M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | -$3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $374.00K derived: sum of 2 quarters · filed 2023-03-01 | -$2.50M derived: sum of 3 quarters · filed 2023-03-01 | -$7.69M 10-K · filed 2023-03-01 | -$8.88M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $4.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.40M derived: sum of 2 quarters · filed 2021-11-04 | -$3.79M 10-Q · filed 2021-11-04 | -$4.43M 10-Q · filed 2020-11-04 | -$3.77M derived: sum of 4 quarters · filed 2022-03-07 | |||
| 2020-06-30 | -$2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$8.07M 10-Q · filed 2021-08-09 | -$8.49M 10-Q · filed 2020-08-10 | -$8.04M derived: sum of 3 quarters · filed 2022-03-07 | -$7.53M derived: sum of 4 quarters · filed 2022-03-07 | |||
| 2020-03-31 | -$5.19M 10-Q · filed 2021-05-04 | -$5.17M derived: sum of 2 quarters · filed 2022-03-07 | -$4.65M derived: sum of 3 quarters · filed 2022-03-07 | $2.94M derived: sum of 4 quarters · filed 2022-03-07 | ||||
| 2019-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $543.00K derived: sum of 2 quarters · filed 2022-03-07 | $8.13M derived: sum of 3 quarters · filed 2022-03-07 | $13.20M 10-K · filed 2022-03-07 | $14.50M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $520.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $8.10M derived: sum of 2 quarters · filed 2020-11-04 | $13.18M 10-Q · filed 2020-11-04 | $14.32M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $7.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $12.66M 10-Q · filed 2020-08-10 | $13.80M derived: sum of 3 quarters · filed 2021-02-25 | $17.65M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $5.08M 10-Q · filed 2020-05-06 | $6.21M derived: sum of 2 quarters · filed 2021-02-25 | $10.06M derived: sum of 3 quarters · filed 2021-02-25 | $12.32M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.99M derived: sum of 2 quarters · filed 2021-02-25 | $7.24M derived: sum of 3 quarters · filed 2021-02-25 | $7.08M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $3.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $6.10M derived: sum of 2 quarters · filed 2019-11-08 | $5.95M 10-Q · filed 2019-11-08 | $7.08M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $2.10M 10-Q · filed 2019-08-08 | $3.23M derived: sum of 3 quarters · filed 2020-03-02 | $2.21M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | -$158.00K 10-Q · filed 2019-05-07 | $979.00K derived: sum of 2 quarters · filed 2020-03-02 | -$40.00K derived: sum of 3 quarters · filed 2020-03-02 | $1.38M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $118.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.54M derived: sum of 3 quarters · filed 2020-03-02 | $2.22M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $399.00K derived: sum of 2 quarters · filed 2018-11-08 | $1.08M 10-Q · filed 2018-11-08 | $1.91M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $2.10M 10-Q · filed 2018-08-07 | $2.93M derived: sum of 3 quarters · filed 2019-02-28 | $2.65M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-03-31 | $682.00K 10-Q · filed 2018-05-08 | $1.51M derived: sum of 2 quarters · filed 2019-02-28 | $1.23M derived: sum of 3 quarters · filed 2019-02-28 | $3.03M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2016-12-31 | $832.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $552.00K derived: sum of 2 quarters · filed 2019-02-28 | $2.34M derived: sum of 3 quarters · filed 2019-02-28 | $1.25M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | -$280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.51M derived: sum of 2 quarters · filed 2017-11-07 | $419.00K 10-Q · filed 2017-11-07 | |||||
| 2016-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $699.00K 10-Q · filed 2017-08-10 | ||||||
| 2016-03-31 | -$1.09M 10-Q · filed 2017-05-12 | |||||||
| 2015-12-31 | $1.95M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |